Pharming Group Nv (PHAR)
NASDAQ:PHAR
Want to see PHAR full AI Analyst Report?
PHAR Stock Chart & Stats
$17.34
>-$0.01(-0.06%)
At close: 4:00 PM EST
$17.34
>-$0.01(-0.06%)
Day’s Range― - ―
52-Week Range$9.30 - $21.34
Previous CloseN/A
Volume11.43K
Average Volume (3M)14.14K
Market Cap
$912.89M
Enterprise Value$1.01B
Total Cash (Recent Filing)$170.90M
Total Debt (Recent Filing)$116.20M
Price to Earnings (P/E)76.9
Beta0.45
Next Earnings
Jul 30, 2026EPS Estimate
0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.18
Shares Outstanding70,625,230
10 Day Avg. Volume8,764
30 Day Avg. Volume14,139
Financial Highlights & Ratios
PEG Ratio-3.59
Price to Book (P/B)4.55
Price to Sales (P/S)3.34
P/FCF Ratio25.55
Enterprise Value/Market Cap1.11
Enterprise Value/Revenue2.74
Enterprise Value/Gross Profit3.14
Enterprise Value/Ebitda25.62
Forecast
1Y Price Target
$38.00Price Target Upside119.15% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)0.12
Revenue Forecast (FY)$397.63M
Bulls Say, Bears Say
Bulls Say
High Gross Margins And ProfitabilitySustained gross margins near 90% indicate durable product economics and pricing power from specialty therapies. Combined with the return to profitability in 2025/TTM, this supports reinvestment in commercialization and R&D, and provides a margin buffer against cost inflation or isolated revenue dips over the next 2–6 months.
Improved Cash Generation And LiquidityConversion to positive operating and free cash flow restores financial flexibility, reducing near‑term reliance on external financing to fund launches and trials. A cash balance (~$171.8M) plus positive OCF supports planned R&D and international launches, increasing the company's ability to execute strategic initiatives over coming quarters.
Regulatory Momentum And International Joenja ExpansionApprovals in Japan (pediatric-inclusive) and positive CHMP backing materially expand addressable markets for leniolisib, diversify revenue beyond RUCONEST, and strengthen reimbursement positioning. These durable regulatory wins support multi-region launch rollouts and long‑term franchise building in ultra‑rare immunodeficiencies.
Bears Say
Revenue Concentration In RUCONESTHeavy reliance on a single commercial product creates structural concentration risk: RUCONEST declines from inventory normalization, competitive entrants, or market exits materially impact revenue and cash generation. With net margins still modest, sustained RUCONEST pressure could strain profitability and slow funding for pipeline expansions.
Regulatory Timing Uncertainty For Pediatric LabelA two‑step resubmission and prior CRL introduce execution and timing risk for pediatric approval, which is central to Joenja's U.S. commercial scaling. Delays compress the expected revenue runway from pediatric uptake and can defer reimbursement negotiations and launch investments, making projected growth more uncertain over the medium term.
Operating Cash Quality And Prior VolatilityAlthough cash flow turned positive recently, OCF below net income signals timing or working‑capital sensitivity and weaker cash quality. Historical negative cash flows in 2023–24 plus one‑time cash drains reduce the buffer for unexpected costs or larger launch investments, limiting runway flexibility if revenue underperforms guidance.
Pharming Group News
PHAR FAQ
What was Pharming Group Nv’s price range in the past 12 months?
Pharming Group Nv lowest stock price was $9.30 and its highest was $21.34 in the past 12 months.
What is Pharming Group Nv’s market cap?
Pharming Group Nv’s market cap is $912.89M.
When is Pharming Group Nv’s upcoming earnings report date?
Pharming Group Nv’s upcoming earnings report date is Jul 30, 2026 which is in 44 days.
How were Pharming Group Nv’s earnings last quarter?
Pharming Group Nv released its earnings results on May 07, 2026. The company reported -$0.07 earnings per share for the quarter, missing the consensus estimate of $0.001 by -$0.071.
Is Pharming Group Nv overvalued?
According to Wall Street analysts Pharming Group Nv’s price is currently Undervalued.
Does Pharming Group Nv pay dividends?
Pharming Group Nv does not currently pay dividends.
What is Pharming Group Nv’s EPS estimate?
Pharming Group Nv’s EPS estimate is 0.06.
How many shares outstanding does Pharming Group Nv have?
Pharming Group Nv has 70,625,230 shares outstanding.
What happened to Pharming Group Nv’s price movement after its last earnings report?
Pharming Group Nv reported an EPS of -$0.07 in its last earnings report, missing expectations of $0.001. Following the earnings report the stock price went down -26.829%.
Which hedge fund is a major shareholder of Pharming Group Nv?
Currently, no hedge funds are holding shares in PHAR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pharming Group Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$38.00 (119.15% Upside)
$38.00 (119.15% Upside)
Blogger Sentiment
Bullish
PHAR Sentiment 70%
Sector Average ―
Sector Average ―
Crowd Wisdom
Positive
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 3.8%
Last 30 Days ▲ 3.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
7.96%
12-Months-Change
Fundamentals
Return on Equity
4.75%
Trailing 12-Months
Asset Growth
21.38%
Trailing 12-Months
Company Description
Pharming Group Nv
Pharming Group N.V. is a biopharmaceutical company dedicated to the creation and commercialization of protein replacement therapies and precision medicines. The firm concentrates its efforts on addressing rare diseases and critical unmet medical needs across the United States, Europe, and other international markets. Its primary commercialized product is Ruconest, a recombinant human C1 esterase inhibitor utilized for the acute treatment of hereditary angioedema. Pharming's development pipeline also includes rhC1INH, which is being investigated for conditions such as pre-eclampsia, acute kidney injury, and COVID-19. Additionally, the company is developing leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) inhibitor designed for patients with activated PI3K delta syndrome, as well as an alpha-glucosidase therapy targeting Pompe and Fabry diseases. The company has established significant collaborations, including a development and licensing agreement with Novartis. It also maintains a strategic partnership with Orchard Therapeutics plc for the research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy intended for hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.
PHAR Company Deck
PHAR Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a constructive outlook driven by strong Joenja growth, meaningful pipeline and regulatory catalysts, and demonstrated cost discipline with positive operating cash flow. These positives offset near‑term revenue variability driven mainly by expected RUCONEST inventory normalization, strategic market exits and short‑term competitive pressure. Management reaffirmed full‑year guidance and highlighted multiple upcoming clinical and commercial events that could drive upside.View all PHAR earnings summariesPHAR Stock 12 Month Forecast
Average Price Target
$38.00
▲(119.15% Upside)
Technical Analysis
Trevi Therapeutics
―
Oric Pharmaceuticals
―
Praxis Precision Medicines
―
ARS Pharmaceuticals
―
Prime Medicine, Inc.
―
Ownership Overview
―
Insiders
<0.01% Mutual Funds
0.08% Other Institutional Investors
99.91% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---